Antihemophilic factor, human recombinant
- Generic Name
- Antihemophilic factor, human recombinant
- Brand Names
- Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 139076-62-3
- Unique Ingredient Identifier
- P89DR4NY54
- Background
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
- Indication
The human recombinant antihemophilic factor is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
- Associated Conditions
- Bleeding, Joint Damage, Perioperative Blood Loss
- Associated Therapies
- -
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath